tradingkey.logo

Check Cap Ltd

CHEK

0.678USD

+0.001+0.15%
Horarios del mercado ETCotizaciones retrasadas 15 min
3.97MCap. mercado
PérdidaP/E TTM

Check Cap Ltd

0.678

+0.001+0.15%
Más Datos de Check Cap Ltd Compañía
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
Información de la empresa
Símbolo de cotizaciónCHEK
Nombre de la empresaCheck Cap Ltd
Fecha de salida a bolsaFeb 19, 2015
Director ejecutivoMr. Alex Ovadia
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 19
Dirección29 Abba Hushi Ave.
Ciudad
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal3009000
Teléfono97248303401
Sitio Webhttps://check-cap.com/
Símbolo de cotizaciónCHEK
Fecha de salida a bolsaFeb 19, 2015
Director ejecutivoMr. Alex Ovadia
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Boaz Shpigelman
Mr. Boaz Shpigelman
Vice President - Research and Development
Vice President - Research and Development
1.23K
+1.49%
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
950.00
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
752.00
--
Ms. Clara Ezed
Ms. Clara Ezed
Independent Director
Independent Director
211.00
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Israel Hershko
Mr. Israel Hershko
Vice President - Quality Assurance and Regulatory Affairs
Vice President - Quality Assurance and Regulatory Affairs
--
--
Mr. Yuval Yanai
Mr. Yuval Yanai
Independent Director
Independent Director
--
--
Dr. Hanit Brenner-lavie
Dr. Hanit Brenner-lavie
Vice President - Clinical Affairs
Vice President - Clinical Affairs
--
--
Mr. Dan Hilerowitz
Mr. Dan Hilerowitz
Chief Financial Officer
Chief Financial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Boaz Shpigelman
Mr. Boaz Shpigelman
Vice President - Research and Development
Vice President - Research and Development
1.23K
+1.49%
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
950.00
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
752.00
--
Ms. Clara Ezed
Ms. Clara Ezed
Independent Director
Independent Director
211.00
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 2 de jul
Actualizado: mié., 2 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
EquityLine Alternate Assets GP Inc
13.04%
Symetryx Corp
5.79%
J.P. Morgan Securities LLC
0.60%
Citadel Advisors LLC
0.36%
BNP Paribas Securities Corp. North America
0.34%
Other
79.87%
Accionistas
Accionistas
Proporción
EquityLine Alternate Assets GP Inc
13.04%
Symetryx Corp
5.79%
J.P. Morgan Securities LLC
0.60%
Citadel Advisors LLC
0.36%
BNP Paribas Securities Corp. North America
0.34%
Other
79.87%
Tipos de accionistas
Accionistas
Proporción
Corporation
18.83%
Research Firm
1.02%
Hedge Fund
0.55%
Investment Advisor/Hedge Fund
0.20%
Individual Investor
0.08%
Other
79.32%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
39
1.57M
26.85%
+1.07M
2025Q1
42
1.57M
26.85%
+1.00M
2024Q4
44
1.61M
27.59%
+1.15M
2024Q3
45
1.48M
25.29%
+968.05K
2024Q2
48
1.48M
25.22%
+958.50K
2024Q1
57
722.40K
12.35%
+185.59K
2023Q4
59
777.23K
13.29%
+83.98K
2023Q3
61
699.06K
11.95%
+309.38K
2023Q2
62
22.37K
0.38%
-595.96K
2023Q1
68
336.11K
6.40%
-190.75K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
EquityLine Alternate Assets GP Inc
762.72K
13.04%
+762.72K
--
Apr 05, 2024
Symetryx Corp
338.63K
5.79%
+37.76K
+12.55%
Nov 27, 2023
J.P. Morgan Securities LLC
35.36K
0.6%
+33.86K
+2257.07%
Mar 31, 2025
Citadel Advisors LLC
20.85K
0.36%
-1.68K
-7.46%
Mar 31, 2025
BNP Paribas Securities Corp. North America
19.84K
0.34%
+6.20K
+45.46%
Mar 31, 2025
Two Sigma Investments, LP
11.48K
0.2%
+11.48K
--
Mar 31, 2025
Dimensional Fund Advisors, L.P.
8.96K
0.15%
--
--
Jan 31, 2025
Morgan Stanley & Co. LLC
3.90K
0.07%
-26.90K
-87.33%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.93K
0.05%
--
--
May 31, 2025
Shpigelman (Boaz)
1.23K
0.02%
+18.00
+1.49%
Apr 01, 2024
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Fecha
Tipo
Relación
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
KeyAI